About Aurobindo Pharma Limited
Aurobindo Pharma Limited (AUROPHARMA) has been publicly traded since 1996, making it a 30-year-old public company. It operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. The company is headquartered in Hyderabad, India and employs approximately 27,707 people. With a market capitalization of $753 billion, AUROPHARMA is one of the largest publicly traded companies.
Key Statistics
- Current Price
- ₹1,296.50
- Market Cap
- ₹753.01B
- 52-Week High
- ₹1,319.80
- 52-Week Low
- ₹1,010.00
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
₹1,000 Invested
Monthly Returns Heatmap
Annual Returns
| Year | Return | Start | End |
|---|---|---|---|
| 2026 | +9.59% | ₹1,183.00 | ₹1,296.50 |
| 2025 | -11.02% | ₹1,329.51 | ₹1,183.00 |
| 2024 | +23.29% | ₹1,078.39 | ₹1,329.51 |
| 2023 | +149.62% | ₹432.02 | ₹1,078.39 |
| 2022 | -39.67% | ₹716.06 | ₹432.02 |
| 2021 | -19.81% | ₹892.96 | ₹716.06 |
| 2020 | +102.95% | ₹439.99 | ₹892.96 |
| 2019 | -37.39% | ₹702.73 | ₹439.99 |
| 2018 | +6.89% | ₹657.42 | ₹702.73 |
| 2017 | +3.22% | ₹636.91 | ₹657.42 |
| 2016 | -23.31% | ₹830.50 | ₹636.91 |
| 2015 | +54.86% | ₹536.28 | ₹830.50 |
| 2014 | +190.43% | ₹184.65 | ₹536.28 |
| 2013 | +110.05% | ₹87.91 | ₹184.65 |
| 2012 | +124.65% | ₹39.13 | ₹87.91 |
| 2011 | -67.41% | ₹120.07 | ₹39.13 |
| 2010 | +46.54% | ₹81.94 | ₹120.07 |
| 2009 | +454.08% | ₹14.79 | ₹81.94 |
| 2008 | -68.64% | ₹47.17 | ₹14.79 |
| 2007 | -22.78% | ₹61.08 | ₹47.17 |
| 2006 | +72.31% | ₹35.45 | ₹61.08 |
| 2005 | +25.87% | ₹28.16 | ₹35.45 |
| 2004 | -23.53% | ₹36.83 | ₹28.16 |
| 2003 | +313.68% | ₹8.90 | ₹36.83 |
| 2002 | -7.29% | ₹9.60 | ₹8.90 |
| 2001 | -53.32% | ₹20.57 | ₹9.60 |
| 2000 | -59.59% | ₹50.90 | ₹20.57 |
| 1999 | +574.62% | ₹7.55 | ₹50.90 |
| 1998 | +68.51% | ₹4.48 | ₹7.55 |
| 1997 | +62.09% | ₹2.76 | ₹4.48 |
Valuation
AUROPHARMA currently trades at a trailing P/E ratio of 21.6, which is considered moderate relative to the broader market. The forward P/E of 17.3 suggests analysts expect earnings to be lower in the coming year. The price-to-book ratio stands at 2.1. The price-to-sales ratio is 2.3.
Dividends
Aurobindo Pharma Limited pays a dividend to shareholders with a current yield of 0.31%. This translates to $4.00 per share annually. The payout ratio of 7% indicates sustainable dividend coverage.
Risk & Volatility
AUROPHARMA has a beta of 0.06, indicating it is less volatile than the overall market. The stock's 52-week range is $1010.00 to $1319.80, and it currently trades near its 52-week high.
Analyst Ratings
Based on 27 analyst opinions, AUROPHARMA has a consensus "buy" rating. The average price target of $1345.19 suggests 3.8% upside from current levels.
Frequently Asked Questions
What does Aurobindo Pharma Limited do? ▼
Aurobindo Pharma Limited is a Drug Manufacturers - Specialty & Generic company operating in the Healthcare sector. The company is headquartered in Hyderabad, India.
What sector is AUROPHARMA in? ▼
AUROPHARMA operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
When did AUROPHARMA go public? ▼
Aurobindo Pharma Limited went public in 1996, making it a 30-year-old public company as of 2026.
How much would $1,000 invested in AUROPHARMA 5 years ago be worth today? ▼
A $1,000 investment in AUROPHARMA five years ago would be worth approximately $1,398 today, representing a 39.8% return.
Does AUROPHARMA pay dividends? ▼
Yes, Aurobindo Pharma Limited pays a dividend with a current yield of 0.31%, which is $4.0 per share annually.
What is AUROPHARMA's market cap? ▼
Aurobindo Pharma Limited has a market capitalization of $753 billion, classifying it as a mega-cap company.
What is AUROPHARMA's P/E ratio? ▼
AUROPHARMA has a trailing P/E ratio of 21.6 and a forward P/E of 17.3, which measures how much investors are paying per dollar of earnings.
Is AUROPHARMA a buy, hold, or sell? ▼
Based on 27 opinions, AUROPHARMA has a consensus "buy" rating. The average price target is $1345.19.
Last updated: 3/14/2026